Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH−), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The DESTINY-CRC01 trial investigated an antibody–drug conjugate (ADC), namely, trastuzumab deruxtecan (T-Dxd), which delivers a payload of chemotherapy directly to HER2-expressing cells [77,78].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredIn the citing paper
“Among 86 enrolled patients, 45.3% had an objective response. Median overall survival was 15.5 months with a reported 6.9-month progression-free survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 4×
“TreatmentselectionforpatientswithmCRCaredependentonthe tumor molecular pro fi le, tumor location, mismatch repair status, and prior therapies received 7,8,17 .”
InfluentialSelf-citationGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“5 months, which is 5 months greater than the reported standard of care in third-line or latermCRC 9,12,13,18 , and merits future studies in this patient population.”
InfluentialSelf-citationTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · cited 2×
“%) had adjudicated drug-related ILD/pneumo-nitis and 3 were grade 5 (3.5%), which was generally similar to the observed incidence across other tumor types 37,45,47 .”
InfluentialSelf-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Self-citation
Cited by
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., Nobrega, M., Ferrier, T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 247
Smit, E. F., Felip, E., Uprety, D., Nagasaka, M., Nakagawa, K., Paz-Ares Rodríguez, L., Pacheco, J. M., Li, B. T., Planchard, D., Baik, C., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00064-0 · Cited by 185
HER2-targeted therapies beyond breast cancer — an update
Yoon, J., & Oh, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00924-9 · Cited by 196
Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., den Eynde, M. V., Pietrantonio, F., Komatsu, Y., Kawakami, H., Peeters, M., André, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00380-2 · Cited by 180
Self-citation
Metadata
- Authors
- Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., Rodriguez, J., Fakih, M., Ciardiello, F., Saxena, K., Kobayashi, K., Bako, E., Okuda, Y., Meinhardt, G., Grothey, A., Siena, S., DESTINY-CRC01 investigators, & Di Bartolomeo, M.
- Affiliations
- National Cancer Center Hospital East (JP)
- The University of Texas MD Anderson Cancer Center (US)
- Aichi Cancer Center Hospital (JP)
- Istituto Oncologico Veneto (IT)
- Kindai University Hospital (JP)
- The Cancer Institute Hospital (JP)
- Shikoku Cancer Center (JP)
- Ronald Reagan UCLA Medical Center (US)
- Clinica Universidad de Navarra (ES)
- City Of Hope National Medical Center (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Daiichi Sankyo (United States) (US)
- Daiichi-Sankyo (Japan) (JP)
- West Cancer Center (US)
- University of Milan (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Siena, Salvatore
- ORCID
- Venue
- Nature Communications
- Published
- 2023-06-07
- Volume
- 14
- Issue
- 1
- Pages
- 3332-3332
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10247780
- OpenAlex
- W4379740210
- Cited by
- 178
- References
- 50
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 58 · 2023: 10
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Daiichi Sankyo and AstraZeneca
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- trastuzumab deruxtecan, antibody-drug conjugates, objective response rate, progression-free survival, overall survival, interstitial lung disease, neutropenia, anemia, HER2 immunohistochemistry, in situ hybridization, treatment-emergent adverse events
- MeSH terms
- Trastuzumab, Breast Neoplasms, Camptothecin, Colonic Neoplasms, Female, Humans, Rectal Neoplasms, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/s41467-023-38032-4
- The paper
- Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., Rodriguez, J., Fakih, M., Ciardiello, F., Saxena, K., Kobayashi, K., Bako, E., Okuda, Y., Meinhardt, G., Grothey, A., . . . Di Bartolomeo, M. (2023). Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nature Communications. https://doi.org/10.1038/s41467-023-38032-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.